While we anticipate that genes outside of MMR pathway are unlikely to explain a large component of suspected familial EC, our results indicate that additional tumor signature analysis for individuals with a germline gene alteration has potential to impact therapeutic decisions. This evidence concerns the gene MRC1 and neoplasm.